- Stereotactic body radiation therapy (SBRT) may be an effective treatment approach in patients with oligoprogressive castration-resistant prostate cancer (CRPC).
- No serious adverse events were reported with SBRT.
Why this matters
- SBRT has shown benefit in oligometastatic castration-sensitive prostate cancer, but its role in CRPC is not known.
- Prospective evaluation of study findings is warranted.
- Multicenter study of 86 patients (117 lesions) with oligoprogressive CRPC who received SBRT.
- Funding: None.
- Median follow-up was 30.7 months.
- Median new metastasis-free survival was 12.3 (95% CI, 5.5-19.1) months.
- 1- and 2-year distant PFS was 52.3% and 33.7%, respectively.
- 26 patients underwent a second course of SBRT.
- Median systemic treatment-free survival was 21.8 (95% CI, 17.8-25.8) months.
- 1-year systemic treatment-free survival was 72.1%.
- Total radiation dose showed significant association with systemic treatment-free survival (biologically effective dose >100 vs ≤100 Gy; P=.004).
- 3 patients experienced grade 1/2 acute intestinal or genitourinary toxicities.
- 2 patients experienced grade 1/2 late intestinal or genitourinary toxicities.
- Retrospective design; lack of comparator group.